‘Disappointed’ UCB And Amgen Will Appeal CHMP’s Negative Evenity Decision
The EMA’s CHMP cited concerns over cardiovascular side effects as the reason why it took a negative stance on Evenity’s use in the EU for treating severe osteoporosis.
You may also be interested in...
Belgium-headquartered UCB has a group of antibody-based products in mid to late-stage clinical studies which will be competing in the dermatology/immune disorders marketplace in the next few years.
Newer products are gaining ground, but not fast enough to replace sales as blockbuster products face competition. Scrip spoke with the company's global commercial head about the strategy going forward.
Four drugs are up for an opinion this week on whether they should be granted EU-wide approval, including Amgen/UCB's osteoporosis drug romosozumab.